Quince Therapeutics Stock Forecast

QNCX's stock price has decreased by -94.33% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 6 analysts polled by S&P Global, Quince Therapeutics stock has a consensus rating of "Buy" and an average price target of $86.67. The average 1-year stock price forecast is 403.02% higher than the current stock price, while the lowest is $80 (+364.31%) and the highest is $100 (+480.38%).

Price Target: $86.67 (+403.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$80	$86.67	$80	$100
Change	+364.31%	+403.02%	+364.31%	+480.38%

Analyst Ratings

The average analyst rating for Quince Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	May '26	Jun '26
Strong Buy	4	4	1	0	0	3
Buy	2	2	0	0	0	0
Hold	0	0	4	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	1	1	0	0
Total	6	6	6	4	3	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Initiates $5	Buy	Initiates	$5	-70.98%	Jun 29, 2026
Joseph Schwartz Leerink Partners	Leerink Partners	Buy Initiates $4	Buy	Initiates	$4	-76.78%	Jun 24, 2026
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $4	Buy	Initiates	$4	-76.78%	Jun 23, 2026
Jason McCarthy Maxim Group	Maxim Group	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Feb 2, 2026
Elemer Piros Lucid Capital	Lucid Capital	Sell Downgrades n/a	Sell	Downgrades	n/a	n/a	Jan 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

12.79M

EPS This Year

-0.27

from -16.80

EPS Next Year

-1.31

from -0.27

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-90.32M	-50.09M	-24.64M	-36.17M	-50.43M	-59.00M
Net Income	-89.95M	-51.66M	-31.39M	-56.83M	-83.98M	-12.05M
EPS	-	-	-	-	-16.80	-0.27
Free Cash Flow	-30.54M	-24.18M	-1.94M	-21.13M	-11.18M	-23.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.10
Avg	-0.27
Low	-0.43

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-